ReviewHormones (Athens, Greece)2025
Distinctive hobnail subtype of papillary thyroid carcinoma: a case series and short review of literature.
Review in Hormones (Athens, Greece), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aggressive follicular cell derived thyroid carcinoma: what do you need from the pathologist.Virchows Archiv : an international journal of pathology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe hobnail subtype of papillary thyroid carcinoma (HSPTC) is a rare and aggressive subtype, comprising 1-2% of all PTC cases. It is characterized by poor prognosis, frequent BRAF and p53 mutations, and a high recurrence rate. Given the limited data on HSPTC, especially in the Indian population, this case series aims to provide valuable insights into its clinical behavior, mutational profile, and treatment outcomes. MATERIALS AND
methodsA retrospective analysis was conducted from January 2021 to December 2023. Histological reports were reviewed for cases with ≥ 5% hobnail features. Cases fulfilling these criteria were reviewed for features of high-grade differentiated thyroid carcinoma. Immunohistochemistry was performed to identify BRAF.V600E and p53. Patient demographics, tumor characteristics, and follow-up data were collected. Follow-up included clinical exams, thyroid function tests, thyroglobulin, anti-thyroglobulin antibody levels, and imaging when necessary.
resultsAmong 600 PTC cases, 4 were identified as HSPTC (0.67% incidence). The median follow-up was 40 months. Mean tumor size of 3.3 cm. 75% showed BRAF and p53 positivity. Lymphovascular invasion (LVI) was present in 50% of patients. Recurrence occurred in two patients, both with LVI, despite receiving radioactive iodine and radiotherapy. The largest tumor (6 cm) did not show lymph node metastasis, while smaller tumors (2.2 cm, 2.3 cm) were metastatic. Higher mitotic rate showed necrosis and lymph nodal metastasis. Neither BRAF nor p53 positivity correlated with thyroglobulin levels.
conclusionHSPTC exhibits aggressive behavior, particularly in cases with LVI, high mitotic activity and necrosis. BRAF and p53 mutations are common and cause aggressiveness. Early and aggressive management are essential to improve outcomes.
Indexed as
Identifiers
40560352What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.